Generic Name and Formulations:
Latanoprost 0.005%; oph soln; contains benzalkonium chloride.
Indications for XALATAN:
Open-angle glaucoma. Ocular hypertension.
1 drop once daily in the PM.
Do not exceed recommended dose (may reduce efficacy). Ocular inflammation. Aphakia. Pseudophakia with torn posterior lens capsule. Risk of macular edema. Contact lenses (remove; may reinsert lenses 15 minutes after administration). Pregnancy (Cat.C). Nursing mothers.
Allow at least 5 minutes between application of other topical oph agents.
Blurred vision, burning, stinging, conjunctival hyperemia, foreign body sensation, itching, increased ocular pigmentation (eg, iris, eyelid, eyelashes; may be permanent), punctate epithelial keratopathy, other eyelash/lid changes, photophobia, upper respiratory tract infection, pain, angina, rash; intraocular inflammation, macular edema (including cystoid macular edema).
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Nomophobia: The Modern-Day Pathology
- Emerging Theories in the Pathophysiology of MDD: Could the Opioid System Be Involved?
- Transdermal Nicotine Boosts Mood and Cognitive Function in Late-Life Depression
- Combination Cognitive Behavioral Therapy With Fluoxetine Effective for Adolescent Depression
- Ketamine Infusions Reduce Suicidal Ideation in Depression: Characterizing Different Responses
- Text Message Reminders Improve Medication Adherence in Bipolar I Disorder
- Improving Medication Adherence in ADHD Lowers Risk for Oppositional Defiant Disorder, Conduct Disorder in Adulthood
- High Suicidality Among Children With ADHD Mediated by Family Functioning, Psychiatry Comorbidities
- Pilot Study Investigates Lithium vs Quetiapine for Bipolar Spectrum Disorder
- How Personalized Hospital Ratings May Drive Patient-Specific Care in the Digital Age